Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female ≥18 years and ≤ 85 years~* colonoscopy procedure indicated~* willing to stay in the outpatient clinical site for colonoscopy and questionnaire completion~* willing and able to undergo study-related procedures~* informed consent signed by a patient for participation in the study~* negative pregnancy test in women with childbearing potential and consent for double barrier method birth control for subjects, men and women, during the study~Exclusion Criteria:~* ileus~* suspected colonic tumor with manifestations of intestinal obstruction~* delayed gastric emptying (gastroparesis), weak vomiting reflex, tendency to aspiration and regurgitation~* toxic megacolon which is a result of severe inflammatory conditions of the colon including Crohn's disease and ulcerative colitis~* suspected intestinal perforation or risk of gastrointestinal perforation~* signs of severe intestinal bleeding~* acute inflammatory anal or perianal pathology~* severe concomitant diseases of internal organs~* psychiatric diseases in aggravation stage~* hypersensitivity to polyethylene glycol and/or any component of MOVIPREP® preparation~* phenylketonuria or diagnosed glucose-6-phosphate dehydrogenate deficiency~* unconsciousness~* dehydration~* severe inflammatory diseases~* acute abdominal pain of unknown etiology~* pregnancy and lactation period~* participation in any other clinical study (including studies of experimental devices) in 30 days prior participation in the present trial~* patients who test positive for human immunodeficiency virus (HIV)/autoimmune disease (AID), Wasserman reaction (RW) or hepatitis B virus (HBC)~* any condition or circumstance that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of study data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MOVIPREP (Morning-only dose) (Type: EXPERIMENTAL): MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
- MOVIPREP (Split-dose) (Type: OTHER): MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).